Literature DB >> 23272993

The impact of psychosomatic co-morbidity on discordance with respect to reasons for encounter in general practice.

Antonius Schneider1, Eva Wartner, Isabelle Schumann, Elisabeth Hörlein, Peter Henningsen, Klaus Linde.   

Abstract

OBJECTIVE: Concordance between general practitioners (GPs) and patients is an essential requirement for treatment success and patient satisfaction in general practice. The objectives of this were to estimate the total amount of discordance with respect to reason for encounter (RFE) during consultation in German general practices, and to explore the influence of psychosomatic co-morbidity of the patients in case of discordance.
METHODS: 1101 consecutive patients completed a questionnaire, including questions about the RFE and the Patient Health Questionnaire (PHQ). RFEs, as stated by the patients and diagnosed by the GPs were matched according to a predefined index. Factors that may influence the level of discordance between patients' RFE and GPs' RFE were analysed.
RESULTS: Amount of concordance was 74.9%, incomplete concordance 11.2%, discordance in different physical RFEs was 9.1%, and discordance when GPs diagnosed psychosomatic illness while patients presented physical complaints was found in 2.5%. The number of RFE (OR 3.03; 95%CI 2.48-3.69; P<.001), depression (OR 2.27; 95%CI 1.51-3.41), anxiety (OR 1.78; 95%CI 1.03-3.10) and somatisation syndrome (OR 2.20; 95%CI 1.50-3.22) significantly predicted incomplete concordance and discordance, respectively. The number of RFE was significantly associated with depression (OR 1.32; 95%CI 1.09-1.61) and somatoform syndrome (OR 1.45; 95%CI 1.21-1.74).
CONCLUSION: The considerable amount of discordance and incomplete concordance can partly be explained by the psychosomatic co-morbidity of the patients. If it is seen as a fundamental right of patients to be adequately understood, more efforts are necessary to improve patient centredness. Further studies have to evaluate if improvement of identification of psychosomatic co-morbidity might reduce discordance.
Copyright © 2012. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2012        PMID: 23272993     DOI: 10.1016/j.jpsychores.2012.09.007

Source DB:  PubMed          Journal:  J Psychosom Res        ISSN: 0022-3999            Impact factor:   3.006


  6 in total

1.  The Treatment of Depression in Primary Care.

Authors:  Sebastian Trautmann; Katja Beesdo-Baum
Journal:  Dtsch Arztebl Int       Date:  2017-10-27       Impact factor: 5.594

2.  Combining the GP's assessment and the PHQ-9 questionnaire leads to more reliable and clinically relevant diagnoses in primary care.

Authors:  Clara Teusen; Alexander Hapfelmeier; Victoria von Schrottenberg; Feyza Gökce; Gabriele Pitschel-Walz; Peter Henningsen; Jochen Gensichen; Antonius Schneider
Journal:  PLoS One       Date:  2022-10-21       Impact factor: 3.752

3.  Patterns of health care utilization for low back pain.

Authors:  Walter F Stewart; Xiaowei Yan; Joseph A Boscarino; Daniel D Maeng; Jack Mardekian; Robert J Sanchez; Michael R Von Korff
Journal:  J Pain Res       Date:  2015-08-12       Impact factor: 3.133

4.  Reasons for encounters and psychiatric comorbidity in an urban Bavarian primary care out-of-hour service - results of a cross sectional study.

Authors:  Constanze Storr; Lucia Marieke Gahbler; Klaus Linde; Antonius Schneider
Journal:  BMC Health Serv Res       Date:  2017-11-28       Impact factor: 2.655

5.  Challenges to patient centredness - a comparison of patient and doctor experiences from primary care.

Authors:  Helene Bodegård; Gert Helgesson; Niklas Juth; Daniel Olsson; Niels Lynøe
Journal:  BMC Fam Pract       Date:  2019-06-15       Impact factor: 2.497

6.  Disease burden in a large cohort of asylum seekers and refugees in Germany.

Authors:  Frank Müller; Evelyn Kleinert; Nele Hillermann; Anne Simmenroth; Eva Hummers; Anna Zychlinsky Scharff; Christian Dopfer; Christine Happle; Alexandra Jablonka
Journal:  J Glob Health       Date:  2021-01-30       Impact factor: 4.413

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.